AICAR

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside, Acadesine, AICA riboside) is a purine nucleoside analog of adenosine and the prototypical pharmacological AMP-activated protein kinase (AMPK) activator. It is not a peptide. Chemically, AICAR is a naturally occurring intermediate in the de novo purine biosynthesis pathway. The pharmacological form is administered parenterally and enters cells through nucleoside transporters. Once intracellular, AICAR is phosphorylated by adenosine kinase (ADK) to form 5-aminoimidazole-4-carboxamide ribonucleotide (ZMP), which structurally mimics AMP and allosterically activates AMPK. AMPK is the cellular energy sensor that triggers catabolic, ATP-producing pathways (fatty acid oxidation, glucose uptake, mitochondrial biogenesis) and suppresses anabolic, ATP-consuming pathways. AICAR has been studied as a research tool since the 1990s and has been investigated clinically for cardiac ischemic preconditioning, prevention of cardiovascular events during coronary artery bypass graft surgery (Phase 3 RED-CABG trial, terminated 2010), hematological malignancies (Phase I/II in MDS/AML and CLL), and metabolic disease. None of these programs achieved regulatory approval. The Narkar 2008 Nature paper demonstrating exercise-mimetic endurance enhancement in mice led to WADA prohibition in 2009 under Section S4.5.1.

Chemistry and Cellular Pharmacology

AICAR (chemical name 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) is a purine nucleoside analog with the imidazole base linked to a ribose sugar. Structurally it differs from adenosine by replacement of the adenine base with the aminoimidazole-carboxamide base. The compound is hydrophilic and crosses cell membranes via nucleoside transporters (particularly ENT1 and ENT2).

Once inside the cell, AICAR is phosphorylated by adenosine kinase (ADK) to form ZMP (AICAR monophosphate). ZMP structurally mimics AMP and binds the AMPK γ-subunit, producing allosteric activation and protection from dephosphorylation of the activating Thr172 site on the AMPK α-subunit. Cells with high adenosine kinase expression (hepatocytes, skeletal muscle) show greater sensitivity to AICAR.

ZMP can also be further phosphorylated to ZDP and ZTP. At higher concentrations, ZTP may have non-AMPK effects including incorporation into nucleic acids and effects on other purine-binding enzymes. These AMPK-independent effects have become increasingly recognized as significant for AICAR pharmacology.

Discovery and Development History

AICAR was originally synthesized in the 1950s as a chemical curiosity and naturally occurring purine intermediate. Pharmaceutical development began in the 1980s when researchers at Gensia Sciences developed AICAR as Acadesine for cardiac ischemic preconditioning. The premise was that AICAR-induced AMPK activation could enhance adenosine release in ischemic tissue and provide cardioprotection.

The clinical development trajectory:

• 1990s: Phase 1, 2, and early Phase 3 trials for cardiac surgery indication
• 2008: Narkar 2008 Nature paper identifying exercise mimetic properties
• 2009: WADA prohibition of AICAR and AMPK activators
• 2010: Phase 3 RED-CABG trial in 7578 patients undergoing CABG surgery, terminated early for futility
• 2010s: oncology investigation in hematological malignancies (MDS/AML, CLL)
• Ongoing: research tool use for AMPK biology

The Narkar 2008 Exercise Mimetic Paper

The Narkar et al. 2008 Cell paper demonstrated that 4 weeks of daily AICAR administration (500 mg/kg/day) to untrained C57BL/6 mice produced significant adaptations: increased running endurance by 44% versus controls, increased expression of mitochondrial and metabolic genes in skeletal muscle, enhanced fatty acid oxidation, and increased mitochondrial biogenesis through PGC-1α activation.

The paper was a landmark for the AMPK field because it demonstrated that pharmacological AMPK activation alone could produce some adaptations classically attributed to exercise training. The combination of AICAR with the PPARδ agonist GW501516 (Cardarine) showed synergistic effects.

The performance-enhancing implications were immediately recognized. WADA added AMPK activators to the Prohibited List in 2009 under Section S4.5, specifying AICAR and SR9009 as examples.

The RED-CABG Phase 3 Trial

RED-CABG (Newman 2012 JAMA) was the largest clinical trial of AICAR. The trial enrolled 7578 patients undergoing CABG surgery, randomized to Acadesine (0.1 mg/kg/min IV for up to 7 hours starting at induction of anesthesia) or placebo. The primary endpoint was a composite of all-cause mortality, non-fatal stroke, or severe left ventricular dysfunction at day 28.

Results: the trial was terminated early for futility. There was no significant difference in the primary endpoint between Acadesine and placebo. Post-hoc analyses raised questions about potential adverse effects in some subgroups. The negative result effectively ended Acadesine development for the cardiac surgery indication.

Hematological Malignancy Research

AICAR has been investigated in hematological malignancies based on observed cytotoxic effects in tumor cell lines and primary samples. In chronic lymphocytic leukemia, in vitro AICAR induced apoptosis in CLL cells. Childhood acute lymphoblastic leukemia cell line studies showed AICAR-induced apoptosis and AMPK activation. In chronic myelogenous leukemia, antiproliferative effects were observed without AMPK dependence. In myelodysplastic syndrome/acute myeloid leukemia, 2 mM AICAR blocked proliferation in azacytidine-refractory cell lines, leading to a Phase I/II clinical trial in 12 patients with Aza-refractory MDS/AML.

AMPK-Independent Effects

A 2021 systematic review (Visnjic 2021 Biomolecules) compiled evidence that many AICAR effects are AMPK-independent. Mechanisms include direct effects of ZMP on AMP-binding enzymes other than AMPK (fructose-1,6-bisphosphatase, glycogen phosphorylase, mTOR), incorporation of phosphorylated AICAR into nucleic acids, depletion of intracellular ATP pools, perturbation of purine nucleotide pool balance, and effects on adenosine receptors.

The AMPK-independent effects complicate interpretation of "AMPK activator" studies using AICAR alone. Many published effects attributed to AMPK may actually reflect AMP mimic effects on other enzymes or non-specific nucleotide pool effects.

Endogenous AICAR and Metabolic Disease

AICAR is a normal intermediate in de novo purine biosynthesis. Elevated endogenous AICAR is associated with AICA-ribosiduria (a rare inborn error of metabolism with elevated AICAR levels, associated with severe neurological developmental defects). Epidemiological associations between elevated endogenous AICAR and metabolic disease have been reported. These observations support caution about chronic exogenous AICAR administration.

Regulatory Status

• FDA: Not approved for any indication. On FDA Category 2 bulks list, prohibiting compounding pharmacy preparation
• EMA: Not approved
• WADA: Prohibited at all times in and out of competition under Section S4.5.1 since 2009
• USADA: Echoes WADA prohibition
• Research-chemical channels: principal access route. Quality varies substantially by supplier

AICAR's mechanism involves intracellular conversion to ZMP, AMP mimicry, and AMPK activation, with additional AMPK-independent effects.

Intracellular Conversion

AICAR enters cells via nucleoside transporters (ENT1, ENT2). Once intracellular, the compound is phosphorylated stepwise by adenosine kinase (ADK), adenylate kinase, and nucleoside diphosphate kinase to form successively ZMP (monophosphate), ZDP (diphosphate), and ZTP (triphosphate). ZMP is the principal active metabolite responsible for AMPK activation.

The phosphorylation step is the rate-limiting and pharmacokinetic-determining step. Cells with high adenosine kinase expression (hepatocytes, skeletal muscle, adipose tissue) accumulate ZMP and show stronger AMPK activation. Cells with low ADK expression are relatively resistant to AICAR.

AMPK Activation Pathway

AMPK is a heterotrimeric kinase composed of catalytic α subunit and regulatory β and γ subunits. ZMP binds the γ-subunit at AMP-binding sites, producing allosteric activation and protecting Thr172 phosphorylation on the α-subunit from dephosphorylation. Activated AMPK then phosphorylates downstream substrates.

Key downstream effects include lipid metabolism (phosphorylation and inhibition of acetyl-CoA carboxylase, reducing malonyl-CoA, increasing CPT1 activity, and increasing fatty acid oxidation), glucose metabolism (GLUT4 translocation and increased glucose uptake, reduced hepatic gluconeogenesis), protein synthesis suppression (inhibition of mTORC1 through TSC2 and Raptor phosphorylation), mitochondrial biogenesis (PGC-1α activation), autophagy (ULK1 activation), and transcriptional effects (PGC-1α, FOXO, and other metabolic transcription factors).

AMPK-Independent Effects

Substantial AICAR pharmacology operates through AMPK-independent mechanisms: ZMP effects on other AMP-binding enzymes (fructose-1,6-bisphosphatase, glycogen phosphorylase), nucleotide pool perturbation, mTOR effects independent of AMPK, increased extracellular adenosine through ADK inhibition, and AMPK-independent cytotoxicity in cancer cells.

Pharmacokinetics

AICAR has poor oral bioavailability and is administered parenterally (IV or SC). Plasma half-life is short (approximately 30 minutes). Distribution is wide due to nucleoside transporter expression. Metabolism includes intracellular phosphorylation to ZMP and subsequent metabolism. Elimination is primarily renal.

Comparison to Other AMPK Activators

Metformin: indirect AMPK activator through complex I inhibition. Clinically approved for type 2 diabetes. Lower potency at direct AMPK activation than AICAR but much better characterized clinical profile.

Salicylate (aspirin): direct AMPK activator at high doses through β1 subunit binding.

A-769662: synthetic direct AMPK activator selective for β1-containing complexes. Research tool.

Compound 991: more potent direct AMPK activator with broader subunit selectivity. Research tool.

Natural compounds: berberine, resveratrol, quercetin, and many traditional medicine compounds activate AMPK through various mechanisms.

Effects in preclinical research (animal studies and cell culture):

• Increased endurance capacity in untrained mice (Narkar 2008 Nature, 44% increase over 4 weeks)
• Enhanced mitochondrial biogenesis through PGC-1α activation
• Increased fatty acid oxidation
• Reduced fatty liver in diet-induced obesity models
• Improved insulin sensitivity in metabolic disease models
• Effects on cardiac ischemic preconditioning
• Anti-tumor effects in hematological malignancy models (often AMPK-independent)
• Effects on adipocyte differentiation and metabolic flexibility
• Effects on aging-related phenotypes in some longevity studies

Effects in human clinical trials:

• RED-CABG (Newman 2012 JAMA): no significant cardioprotection during CABG surgery, trial terminated for futility
• MDS/AML Phase I/II: limited efficacy data in azacytidine-refractory disease
• Earlier CLL studies: variable response in small cohorts

Effects in off-label community use:

• Anecdotal reports of endurance enhancement
• Reported fat loss enhancement on rest days
• Substantial individual variation
• No controlled comparative data

Adverse effects observed in clinical trials and animal studies:

• Hyperuricemia and gout flares
• Hypoglycemia (especially with concomitant metformin, insulin, sulfonylureas)
• Possible hepatotoxicity at high doses
• Hematological effects (cytopenias)
• Significant injection site reactions
• Concerns about chronic AMPK activation leading to neurodegenerative or cell-cycle effects

Honest evidence framing: AICAR is a well-characterized research tool with established preclinical effects on AMPK signaling and metabolic adaptations. The Narkar 2008 endurance mimetic finding is real but has not translated to validated human use. The principal completed Phase 3 trial (RED-CABG in cardiac surgery) was terminated for futility. The compound has substantial AMPK-independent effects that complicate "AMPK activator" claims. Serious safety concerns exist including neurodegeneration, hyperuricemia, hypoglycemia, and AMPK-independent cytotoxicity. WADA prohibition is unambiguous. For users seeking exercise-mimetic effects, actual exercise has substantially stronger evidence and lacks the safety concerns of pharmacological AMPK activation.

Important note: AICAR has no FDA-approved dosing and significant safety concerns. The doses described below come from clinical trial protocols and off-label community use, not validated therapeutic protocols.

Clinical trial doses (research contexts, not personal use):

• RED-CABG Phase 3 (cardiac surgery): 0.1 mg/kg/min IV infusion for up to 7 hours (approximately 400-500 mg total dose)
• Oncology Phase I/II (MDS/AML): 50-500 mg IV doses, variable schedules
• Cardiac ischemic preconditioning research: 1-5 mg/kg IV bolus

Off-label community protocols (no clinical evidence supporting):

• 25-100 mg subcutaneously
• 3-5 times per week
• Short cycles of 2-4 weeks
• Administration on rest days to avoid interference with training-day signaling

Routes:

• Intravenous: clinical research standard
• Subcutaneous: principal off-label route. Slower absorption profile
• Oral: poor bioavailability, not used in research protocols

Dangerous combinations:

• Metformin: significant additive AMPK activation and hypoglycemia risk
• Insulin: severe hypoglycemia risk
• Sulfonylureas: severe hypoglycemia risk
• Other AMPK activators: cumulative effects unclear, theoretical risks

Special populations:

• Pregnancy: contraindicated. No safety data
• Breastfeeding: avoid
• Pediatric: contraindicated
• Diabetics on hypoglycemic medications: significant hypoglycemia risk, contraindicated without medical supervision
• Active malignancy: theoretical concerns about both pro- and anti-tumor effects depending on cancer type
• Active gout or hyperuricemia: contraindicated
• Hepatic impairment: avoid
• Renal impairment: dose adjustment likely needed
• Athletes subject to WADA testing: prohibited at all times

Adverse effects observed in clinical trials and preclinical research:

Acute effects:

• Injection site reactions
• Hypoglycemia (particularly with concomitant diabetes medications)
• Headache
• Nausea
• Hyperuricemia
• Cardiac arrhythmias (reported in some clinical trials)
• Anaphylaxis (rare)

Subacute and chronic theoretical concerns:

• Neurodegeneration: excessive or wrong-tissue AMPK activation has been associated with neurodegenerative effects in animal models
• Cell cycle effects: chronic AMPK activation can prevent cell division, with theoretical implications for tissue maintenance
• Cancer effects: variable depending on context. Anti-tumor effects in hematological malignancies but possible pro-tumor effects in some solid tumors
• Metabolic effects: chronic AICAR exposure may affect glucose homeostasis
• Hepatic effects: liver AMPK activation could affect hepatic function in chronic use
• Renal effects: theoretical concerns with chronic administration
• Bone marrow effects: hematological toxicity observed in oncology trials

RED-CABG-specific safety findings:

The Phase 3 RED-CABG trial in 7578 cardiac surgery patients was terminated for futility, not safety, but post-hoc analyses raised questions about potential adverse effects in some subgroups including possible increased mortality. The negative trial result and ambiguous safety signal contributed to discontinuation of cardiac surgery development.

Research-chemical quality concerns:

• Identity verification varies substantially
• Purity may include synthesis byproducts with their own pharmacology
• Endotoxin contamination concerns for parenteral preparations
• No FDA quality oversight

Contraindications and cautions:

• Active or recent malignancy
• Diabetes on hypoglycemic medications without medical supervision
• Active gout or hyperuricemia
• Hepatic impairment
• Pregnancy and breastfeeding
• Pediatric use
• Athletes subject to WADA testing

Drug interactions:

• Metformin: additive AMPK activation, severe hypoglycemia risk
• Insulin and oral hypoglycemics: severe hypoglycemia risk
• Allopurinol and uric acid-modifying drugs: complex interaction with purine metabolism
• Adenosine receptor modulators: potential additive effects
• Methotrexate and antifolates: theoretical interaction with one-carbon metabolism
• Other AMPK activators: cumulative effects with safety implications

Pregnancy, breastfeeding, pediatric: avoid.

Athletes: WADA-prohibited at all times.

AICAR sits within the AMPK activator class of metabolic modulators. Its closest comparators:

• Metformin (not in peptscope as it is a small molecule pharmaceutical): clinically approved indirect AMPK activator. The gold standard for AMPK-related metabolic intervention with established safety, efficacy, and regulatory approval
• Methylene Blue: different mechanism (mitochondrial electron carrier and MAO inhibitor), but related in the "metabolic optimization" research-chemical space
• NAD+ and NMN: NAD+ precursor approaches to mitochondrial function, different mechanism from AMPK activation but conceptually related
• MOTS-c: mitochondrial-derived peptide with AMPK-related effects
• SS-31 (Elamipretide): mitochondrial-targeted peptide with different mechanism

In off-label research-chemical use, AICAR is sometimes paired with:

• Cardarine (GW501516): PPARδ agonist, also WADA-prohibited. The Narkar 2008 Nature paper demonstrated synergistic exercise-mimetic effects. Both compounds are doping violations
• Stenabolic (SR9009): REV-ERB agonist with metabolic effects. Also WADA-prohibited
• Anabolic-androgenic steroids: combined in some performance contexts. Additional doping violations

Combinations to absolutely avoid:

• Metformin: severe hypoglycemia risk through additive AMPK activation
• Insulin or sulfonylureas: severe hypoglycemia risk
• Other AMPK activators: cumulative effects with safety implications
• Pregnancy and breastfeeding: contraindicated
• Active malignancy: complex risk-benefit, requires oncological supervision
• Hepatic or severe renal impairment: dose adjustment or avoidance

The most actionable framing of AICAR in 2026: this is a purine nucleoside research chemical (Acadesine, 5-aminoimidazole-4-carboxamide ribonucleoside) that activates AMP-activated protein kinase (AMPK) after intracellular phosphorylation to ZMP. The compound is the prototypical pharmacological AMPK activator and has been important as a research tool in metabolic biology since the 1990s. Despite extensive clinical investigation (Phase 3 RED-CABG cardiac surgery trial terminated for futility 2010, Phase I/II oncology), AICAR has not achieved FDA approval for any indication. The Narkar 2008 Nature paper demonstrating endurance enhancement in mice led to WADA prohibition under Section S4.5.1 in 2009. AICAR remains banned at all times for athletes. The compound has substantial AMPK-independent effects that complicate "AMPK activator" claims, and serious safety concerns exist including neurodegeneration, hypoglycemia with diabetes medications, hyperuricemia, hematological effects, and cancer-context cytotoxicity. For users seeking exercise-mimetic effects, actual exercise training has substantially stronger evidence and avoids the safety concerns of pharmacological AMPK activation. For metabolic optimization, lifestyle modifications and approved medications (metformin where clinically indicated) have much better evidence bases than AICAR.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.